文献速递流行病学与生物统计

SARS-CoV-2 B.1.1.7变异株的传入与扩散及再感染情况:卡塔尔全国代表性队列研究

Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study.
PubMed 文献 · PLoS Med · 2021-12-16

该研究在卡塔尔全国队列中描述SARS-CoV-2 B.1.1.7变异株的传入与扩散,并评估自然感染对再感染的效力。B.1.1.7于2020年12月25日首次在卡塔尔发现,传染性比原始循环变异株高约60%。既往PCR确诊感染者对B.1.1.7再感染的自然感染效力为97.5%(95%CI:95.7%至98.6%)。

要点

  • B.1.1.7于2020年12月25日首次在卡塔尔发现,2021年1月18日起突发大规模流行扩散,触发第二波疫情。
  • B.1.1.7传染性比原始循环变异株高约60%。
  • 既往PCR确诊感染者对B.1.1.7再感染的自然感染效力为97.5%(95%CI:95.7%至98.6%)。

核心结论

  • B.1.1.7传入无免疫人群可造成大规模流行波,但既往感染者的自然免疫与B.1.1.7或其他变异株再感染发生率有限强烈相关。

研究设计与样本

  • 全国队列研究,纳入158,608名既往PCR确诊感染者及42,848名抗体阳性者,并设132,701名抗体阴性者作为全国对照队列。

主要发现

  • B.1.1.7于2020年12月25日首次在卡塔尔发现,2021年1月18日起出现突发大规模流行扩散,触发第一波后7个月的第二波疫情。
  • B.1.1.7传染性比原始(野生型)循环变异株高约60%。
  • 既往PCR确诊感染者中,自然感染对再感染的效力:B.1.1.7为97.5%(95%CI:95.7%至98.6%),未知状态变异株为92.2%(95%CI:90.6%至93.5%)。
  • 抗体阳性者中,自然感染对再感染的效力:B.1.1.7为97.0%(95%CI:92.5%至98.7%),未知状态变异株为94.2%(95%CI:91.8%至96.0%)。

局限性

  • 再感染评估基于有记录的PCR确诊再感染,其他再感染可能发生但未被记录。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The epidemiology of the SARS-CoV-2 B.1.1.7 (or Alpha) variant is insufficiently understood. This study's objective was to describe the introduction and expansion of this variant in Qatar and to estimate the efficacy of natural infection against reinfection with this variant. METHODS AND FINDINGS: Reinfections with the B.1.1.7 variant and variants of unknown status were investigated in a national cohort of 158,608 individuals with prior PCR-confirmed infections and a national cohort of 42,848 antibody-positive individuals. Infections with B.1.1.7 and variants of unknown status were also investigated in a national comparator cohort of 132,701 antibody-negative individuals. B.1.1.7 was first identified in Qatar on 25 December 2020. Sudden, large B.1.1.7 epidemic expansion was observed starting on 18 January 2021, triggering the onset of epidemic's second wave, 7 months after the first wave. B.1.1.7 was about 60% more infectious than the original (wild-type) circulating variants. Among persons with a prior PCR-confirmed infection, the efficacy of natural infection against reinfection was estimated to be 97.5% (95% CI: 95.7% to 98.6%) for B.1.1.7 and 92.2% (95% CI: 90.6% to 93.5%) for variants of unknown status. Among antibody-positive persons, the efficacy of natural infection against reinfection was estimated to be 97.0% (95% CI: 92.5% to 98.7%) for B.1.1.7 and 94.2% (95% CI: 91.8% to 96.0%) for variants of unknown status. A main limitation of this study is assessment of reinfections based on documented PCR-confirmed reinfections, but other reinfections could have occurred and gone undocumented. CONCLUSIONS: In this study, we observed that introduction of B.1.1.7 into a naïve population can create a major epidemic wave, but natural immunity in those previously infected was strongly associated with limited incidence of reinfection by B.1.1.7 or other variants.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study. PLoS Med. 2021. PMID: 34914711. doi:10.1371/journal.pmed.1003879

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。